C4 Therapeutics, Inc.
CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkinā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.34
Price-1.68%
-$0.04
1Y
Price
Market Cap
$166.555m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-441.0%
EBITDA Margin-402.6%
Net Profit Margin-189.4%
Free Cash Flow MarginRevenue
$34.240m
-3.8%
1y CAGR+11.5%
3y CAGR+0.6%
5y CAGREarnings
-$111.581m
-5.9%
1y CAGR+3.7%
3y CAGR-10.4%
5y CAGREPS
-$1.58
-3.9%
1y CAGR+12.4%
3y CAGR-1.7%
5y CAGRBook Value
$174.064m
$296.527m
Assets$122.463m
Liabilities$62.923m
DebtDebt to Assets
21.2%
-0.6x
Debt to EBITDAFree Cash Flow
-$87.575m
-34.0%
1y CAGR+2.8%
3y CAGR-4.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company